Redwood City, CA, United States of America

Yuhua Ji

This inventor holds 35 USPTO granted patents and 1 published patent application and 1 EPO patent, primarily in Muscarinic Receptor Antagonists. Top assignees: Theravance, Inc., The General Hospital Corporation, Theravance Biopharma R&d IP, LLC. Active years: 2010-2019.

USPTO Granted Patents = 35 

% Patents Active = 31.4

 

Average Co-Inventor Count = 4.9

ph-index = 9

Forward Citations = 205(Granted Patents)


Company Filing History:


Years Active: 2010-2019

Loading Chart...
Loading Chart...
Areas of Expertise:
Muscarinic Receptor Antagonists
Quaternary Ammonium Compounds
Biphenyl Compounds
Amidine-Containing Compounds
Guanidine-Containing Compounds
Ischemic Disorders
Degenerative Disorders
Therapeutic Compositions
35 patents (USPTO):Explore Patents

Title: The Innovative Journey of Yuhua Ji

Introduction:

Yuhua Ji, a visionary inventor based in Redwood City, CA, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents:

Yuhua Ji holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his expertise in cutting-edge technologies.

Career Highlights:

With a background in computer science and engineering, Yuhua Ji has a proven track record of developing revolutionary solutions that have reshaped industries. His work has been recognized for its creativity and practicality.

Collaborations:

Throughout his career, Yuhua Ji has collaborated with leading tech companies and research institutions to further advance the boundaries of innovation. His partnerships have led to the development of pioneering technologies that have had a lasting impact.

Conclusion:

Yuhua Ji's relentless pursuit of innovation and his passion for pushing the boundaries of what is possible make him a true trailblazer in the world of technology. His work continues to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…